Combating antimicrobial resistance in hospitals

Expert Opinion on Therapeutic Targets

Volumn 3, Issue 1, 1999, Pages 73-88

  Roth, Virginia R ^a   Jarvis, William R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0003018647     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.3.1.73     Document Type: Article

References (153)

1. BRYCE EA, SMITH JA: Focused microbiological surveillance and gram-negative beta-lactamase-mediated resistance in an intensive care unit. Infect. Contr. Hosp. Epidemiol. (1995) 16(6):331-334.
2. GAYNES R: Antibiotic resistance in ICUs: a multifaceted problem requiring a multifaceted solution. Infect. Contr. Hosp. Epidemiol. (1995) 16(6):328-330.
3. ARCHIBALD L, PHILLIPS L, MONNET D, MCGOWAN JE Jr., TENOVER FC, GAYNES RP: Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin. Infect. Dis. (1997) 24:211-215.
4. TOMASZ A: Multiple-antibiotic-resistant pathogenic bacteria-a report on the Rockefeller University workshop. New Engl. J. Med. (1994) 330(17):1247-1251.
5. MCGOWAN JE Jr.: Antibiotic resistance in hospital bacteria: current patterns, modes for appearance or spread, and economic impact. Rev. Med. Microbiol. (1991) 2:161-169.
6. HOLMBERG SD, SOLOMON SL, BLAKE PA: Health and economic impacts of antimicrobial resistance. Rev. Infect. Dis. (1987) 9(6):1065-1078.
7. US CONGRESS, OFFICE OF TECHNOLOGY ASSESSMENT: Impacts of antibiotic-resistant bacteria [OTA-H-629]. US Government Printing Office, Washington DC, USA (1995).
8. ROMERO-VIVAS J, RUBIO M, FERNANDEZ C, PICAZO JJ: Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. (1995) 21(6):1417-1423.
9. EMORI TG, GAYNES RP: An overview of nosocomial infections, including the role of the microbiology laboratory. Clin. Microbiol. Rev. (1993) 6(4):428-442.
10. BREWER TF, HEYMANN SJ, ETTLING M: An effectiveness and cost analysis of presumptive treatment for Mycobacterium tuberculosis. Am. J. Infect. Contr. (1998) 26(3):232-238.
11. CENTERS FOR DISEASE CONTROL: Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan, .1996. MMWR Morb. Mortal. Wkly. Rep. (1997) 46:624-626.
12. VOSS A, MILATOVIC D, WALLRAUCH-SCHWARTZ C, ROSDAHL VT, BRAVENY I: Methicillin-resistant Staphylococcus aureus in Europe. Eur. J. Clin. Microbiol. Infect. Dis. (1994) 13(1):50-55.
13. HASHIMOTO H, INOUE M, HAYASHI I: A survey of Staphylococcus aureus for typing and drug-resistance in various areas of Japan during 1992 and 1993. Jap. J. Antibiotics (1994) 47(6):618-623.
14. HIRAMATSU K, HANAKI H, YABUTA K, OGURI T, TENOVER FC: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. (1997) 40(1):135-136.
15. CENTERS FOR DISEASE CONTROL: Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1996. MMWR Morb. Mortal. Wkly. Rep. (1997) 46(33):765-766.
16. CENTERS FOR DISEASE CONTROL: Update: Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1996. MMWR Morb. Mortal. Wkly. Rep. (1997) 46(35):813-815.
17. ROTUN SS, MCMATH V, SCHOONMAKER DJ et al.: Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg. Infect. Dis. (In Preparation). Also available at http://www.cdc.gov/ncidod/EID/eid.htm.
18. SMITH TL, PEARSON ML, WILCOX KR et al.: Emergence of vancomycin resistance in Staphylococcus aureus: epidemiology and clinical significance. New Engl. J. Med. (In Preparation).
19. HIRAMATSU K, ARITAKA N, HIDEAKI H et al.: Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet (1997) 350(9092):1670-1673.
20. HOWE RA, BOWKER KE, WALSH TR, FEEST TG, MACGOWAN AP: Vancomycin-resistant Staphylococcus aureus. Lancet (1998) 351(9102):602.
21. BANERJEE SN, EMORI TG, CULVER DH et al.: Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am. J. Med. (1991) 91(3B):86S-89S.
22. WENZEL RP, NETTLEMAN MD, JONES RN, PFALLER MA: Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures. Am. J. Med. (1991) 91(Suppl. 3B):221S-227S.
23. TENOVER FC: Novel and emerging mechanisms of antimicrobial resistance in nosocomial pathogens. Am. J. Med. (1991) 91(Suppl. 3B):76S-81S.
24. GARRETT DO, JOCHIMSEN E, MURFITT K et al.: The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect. Contr. Hosp. Epidemiol. (In Preparation).
25. SCHWALBE RS, STAPLETON JT, GILLIGAN PH: Emergence of vancomycin resistance in coagulase-negative staphylococci. New Engl. J. Med. (1987) 316(15):927-931.
26. VEACH LA, PFALLER MA, BARRETT M, KOONTZ FR, WENZEL RP: Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J. Clin. Microbiol. (1990) 28(9):2064-2068.
27. MURRAY BE: The life and the times of the Enterococcus. Clin. Microbiol. Rev. (1990) 3(1):46-65.
28. WOODFORD N, JOHNSON AP, MORRISON D, SPELLER DC: Current perspectives on glycopeptide resistance. Clin. Microbiol. Rev. (1995) 8(4):585-615.
29. ENA J, DICK RW, JONES RN, WENZEL RP: The epidemiology of intravenous vancomycin usage in a university hospital. JAMA (1993) 269(5):598-602.
30. SHAY DK, MALONEY SA, MONTECALVO M et al.: Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J. Infect. Dis. (1995) 172(4):993-1000.
31. MORRIS JG, SHAY DK, HEBDEN JN et al.: Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemnicity in a university medical center. Ann. Int. Med. (1995) 123(4):250-259.
32. HUYCKE MM, SAHM DF, GILMORE MS: Multiple-drug resistant enterococci: The nature of the problem and an agenda for the future. Emerg. Infect. Dis. (1998) 4(2):239-249.
33. NOBEL WC, VIRANI Z, CREE RG: Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol. Lett. (1992) 72:195-198.
34. PIDDOCK LJ, WALTERS RN, JIN YF et al.: Prevalence and mechanism of resistance to 'third-generation' cephalosporins in clinically relevant isolates of Enterobacteriaceae from 43 hospitals in the UK, 1990-1991. J. Antimicrob. Chemother. (1997) 39(2):177-187.
35. LIVERMORE DM, YUAN M: Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J. Antimicrob. Chemother. (1996) 38(3):409-424.
36. NEUWIRTH C, SIEBOR E, LOPEZ J, PICHINOT A, KAZMIERCZAK A: Outbreak of TEM-24-producing Enterobacter aerogenes in an intensive care unit and dissemination of the extended-spectrum betalactamase to other members of the family Enterobacteriaceae. J. Clin. Microbiol. (1996) 24(1):76-79.
37. YUAN M, AUCKEN H, HALL LM, PITT TL, LIVERMORE DM: Epidemiological typing of Klebsiellae with extendedspectrum beta-lactamases from European intensive care units. J. Antimicrob. Chemother. (1998) 41(5):527-539.
38. COHN DL, BUSTREO F, RAVIGLIONE MC: Drug-resistant tuberculosis: Review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. Clin. Infect. Dis. (1997) 24(Suppl. 1):S121-S130.
39. CENTERS FOR DISEASE CONTROL: Nosocomial transmission of multidrug-resistant tuberculosis to healthcare workers and HIV infected patients in an urban hospital-Florida. MMWR Morb. Mortal. Wkly. Rep. (1990) 39(40):718-722.
40. CENTERS FOR DISEASE CONTROL: Transmission of multidrug-resistant tuberculosis from an HIV-positive client in a residential substance-abuse treatment facility-Michigan. MMWR Morb. Mortal. Wkly. Rep. (1991) 40(8):129-131.
41. CENTERS FOR DISEASE CONTROL: Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons-Florida and New York, 1988-.1991. MMWR Morb. Mortal. Wkly. Rep. (1991) 40(34):578-591.
42. CENTERS FOR DISEASE CONTROL: Transmission of multi-drug resistant tuberculosis among immunocompromised persons in a correctional system-NewYork, .1991. MMWR Morb. Mortal. Wkly. Rep. (1992) 41(28):507-509.
43. KENYON TA, RIDZON R, LUSKIN-HAWK R et al.: A nosocomial outbreak of multidrug-resistant tuberculosis. Ann. Int. Med. (1997) 127(1):32-36.
44. FRIDKIN SK, WEBEL SF, WEINSTEIN RA: Magnitude and prevention of nosocomial infections in the intensive care unit. Infect. Dis. Clin. N. Am. (1997) 11(2):479-496.
45. PFALLER MA, HERWALDT LA: The clinical microbiology laboratory and infection control: emerging pathogens, antimicrobial resistance, and new technology. Clin. Infect. Dis. (1997) 25(4):858-870.
46. GHANNOUM MA, REX JH, GALGIANI JN: Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J. Clin. Microbiol. (1996) 34(3):489-495.
47. ABI-SAID DAE, UZUN O, RAAD IPH, VARTIVARIAN S: The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. (1997) 24(6):1129-1130.
48. WINGARD JR: Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clin. Infect. Dis. (1994) 19(Suppl. 1):S49-S53.
49. BARCHIESI F, HOLLIS RJ, DEL POETA M et al.: Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis. Clin. Infect. Dis. (1995) 21(3):561-564.
50. SPEERT DP: Antimicrobial resistance: implications for therapy of infections with common childhood pathogens. Can. J. Infect. Dis. (1996) 7(3):169-173.
51. COL NF, O'CONNER RW: Estimating the worldwide current antibiotic usage: report of Task Force 1. Rev. Infect. Dis. (1987) 9(Suppl. 1):S232-S243.
52. BAQUERO F: Antibiotic resistant in Spain: what can be done? Clin. Infect. Dis. (1996) 23(4):819-823.
53. PHELPS CE: Bug/drug resistance. Sometimes less is more. Med. Care (1989) 27(2):194-203.
54. HOLMBERG SD, OSTERHOLM MT, SENGER KA, COHEN ML: Drug-resistant salmonella from animals fed antimicrobials. New Engl. J. Med. (1984) 311(10):617-622.
55. LEVY SB, FITZGERALD GB, MACONE AM: Changes in intestinal flora of farm personnel after introduction of a tetracycline-supplemented feed on a farm. New Engl. J. Med. (1976) 295(11):583-588.
56. LEVY SB: Multidrug resistance-a sign of the times. New Engl. J. Med. (1998) 338(19):1376-1378.
57. GAYNES R: The impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hospitals. Infect. Dis. Clin. N. Am. (1997) 11(4):757-765.
58. MCGOWAN JE Jr.: Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev. Infect. Dis. (1983) 5(6):1033-1048.
59. BALLOW CH, SCHENTAG JJ: Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. Diagn. Microbiol. Infect. Dis. (1992) 15(2 Suppl):37S-42S.
60. COURCOL RJ, PINKAS M, MARTIN GR: A seven-year survey of antibiotic susceptibility and its relationship with usage. J. Antimicrob. Chemother. (1989) 23(3):441-451.
61. MONNET DL, ARCHIBALD LK, PHILLIPS L et al.: Antimicrobial use and resistance in eight US hospitals: complexities of analysis and modelling. Infect. Contr. Hosp. Epidemiol. (1998) 19(6):388-394.
62. RIDLEY M, LYNN R, BARRIE D, STEAD KC: Antibioticresistant Staphylococcus aureus and hospital antibiotic policies. Lancet (1970) 1(7640):230-233.
63. SHULMAN JA, TERRY PM, HOUGH CE: Colonization with gentamicin-resistant Pseudomonas aeruginosa, pyocine Type 5, in a burn unit. J. Infect. Dis. (1971) 124(Suppl.):S18-S22.
64. COMMETTA A, CALANDRA T, BILLE J, GLAUSER MP: Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. New Engl. J. Med. (1993) 330(17):1240-1241.
65. SCHENTAG JJ, HYATT JM, CARR JR et al.: Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clin. Infect. Dis. (1998) 26(5):1204-1214.
66. BOYCE JM, WHITE RL, CAUSEY WA, LOCKWOOD WR: Burn units as a source of methicillin-resistant Staphylococcus aureus infections. JAMA (1983) 249(20):2803-2807.
67. EDMOND MB, OBER JF, WEINBAUM DL et al.: Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin. Infect. Dis. (1995) 20(5):1126-1133.
68. PLESSIS P, LAMY T, DONNIO PY et al.: Epidemiologic analysis of glycopeptide-resistant Enterococcus strains in neutropenic patients receiving prolonged vancomycin administration. Eur. J. Clin. Microbiol. Infect. Dis. (1995) 14(11):959-963.
69. QUALE J, LANDMAN D, SAURINA G et al.: Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin. Infect. Dis. (1996) 23(5):1020-1025.
70. FLAHERTY JP, WEINSTEIN RA: Nosocomial infection caused by antibiotic-resistant organisms in the intensive-care unit. Infect. Contr. Hosp. Epidemiol. (1996) 17(4):236-248.
71. GREENWOOD D: Tarnished gold: sixty years of antimicrobial drug use and misuse. J. Med. Microbiol. (1995) 43(6):395-396.
72. MCGOWAN JE Jr., GERDING DN: Does antibiotic restriction prevent resistance? New Horizons (1996) 4(3):370-376.
73. JARVIS WR: Preventing the emergence of multidrugresistant microorganisms through antimicrobial use controls: the complexity of the problem. Infect. Contr. Hosp. Epidemiol. (1996) 17(8):490-495.
74. MCGOWAN JE Jr.: Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect. Contr. Hosp. Epidemiol. (1994) 15(7):478-483.
75. www.who.int/emc/diseases/zoo/zoo97-4.html The medical impact of the use of antimicrobials in food animals. In: Report of a WHO Meeting in Berlin, Germany 13-17 October 1997. World Health Organisation, Geneva (1997).
76. MCGOWAN JE Jr., TENOVER FC: Control of antimicrobial resistance in the health care system. Infect. Dis. Clin. N. Am. (1997) 11(2):297-311.
77. MARR JJ, MOFFAT HL, KUNIN CM: Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the Infectious Diseases Society of America. J. Infect. Dis. (1988) 157(5):869-876.
78. CENTERS FOR DISEASE CONTROL: Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practice Advisory Committee (HICPAC). MMWR Morb. Mortal. Wkly. Rep. (1995) 44(RR-12):1-13.
79. SHLAES DM, GERDING DN, JOHN JF et al.: SHEA IDSA joint committee on the prevention of antimicrobial resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Clin. Infect. Dis. (1997) 25(3):584-599.
80. GOLDMANN DA, WEINSTEIN RA, WENZEL RP et al.: Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA (1996) 275(3):234-240.
81. KRITCHEVKY SB, SIMMONS BP: Toward better antibiotic use in hospitals. Infect. Contr. Hosp. Epidemiol. (1994) 15(11):688-690.
82. KOSECOFF J, CHASSIN MR, FINK A et al.: Effects of the National Institutes of Health Consensus Development Program on physician practice. JAMA (1987) 258(19):2538-2542.
83. PICHETTE SC: Clinical practice guidelines in patients' charts may decrease vancomycin use. Cause (1998) 2(2):3.
84. RECCO RA, GLADSTONE JL, FRIEDMAN SA, GERKEN EH: Antibiotic control in a municipal hospital. JAMA (1979) 241(21):2283-2286.
85. MCGOWAN JE Jr., FINLAND M: Effects of monitoring the usage of antibiotics: an interhospital comparison. South Med. J. (1976) 69(2):193-195.
86. KLEM C, DASTA JF: Efforts of pharmacy to reduce antibiotic resistance. New Horizons (1996) 4(3):377-384.
87. MCGOWAN JE Jr.: Minimizing antimicrobial resistance in hospital bacteria: can switching or cycling drugs help? Infect. Contr. (1986) 7(12):573-576.
88. BONHOEFFER S, LIPSITCH M, LEVIN BR: Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. USA (1997) 94(22):12106-12111.
89. DUA V, KUNNIN CM, WHITE LV: The use of antimicrobial drugs in Nagpur, India. A window on medical care in a developing country. Social Sci. & Med. (1994) 38(5):717-724.
90. BOJALIL R, CALVA JJ, ORTEGA H: The use of antibiotics in a community of Mexico City. I. A household survey. Boletin Medico del Hosptial Infantil de Mexico (1993) 50(2):79-87.
91. ADU-SARKODIE YA: Antimicrobial self medication in patients attending a sexually transmitted diseases clinic. Internatl. J. STD & AIDS (1997) 8(7):456-458.
92. LEVY SB: Antibiotic resistance worldwide-a Spanish task force responds. Clin. Infect. Dis. (1996) 23(4):824-826.
93. MAHMOUDI A, ISEMAN MD: Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. JAMA (1993) 270(1):65-68.
94. ISEMAN MD, MADSEN L, GOBLE M, POMERANTZ M: Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. Am. Rev. Resp. Dis. (1990) 141(3):623-625.
95. WEIS SE, SLOCUM PC, BLAIS FX et al.: The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. New Engl. J. Med. (1994) 330(17):1179-1184.
96. JOHNSON MW, MITCH WE, HELLER AH, SPECTOR R: The impact of an educational program on gentamicin use in a teaching hospital. Am. J. Med. (1982) 73(1):9-14.
97. GILBERT DN, EUBANKS NM, JACKSON JM: The effects of monitoring the use of gentamicin in a community hospital. J. Med. Educat. (1978) 53(2):129-134.
98. JONES SR, PANNELL J, BARKS J et al.: The effect of an educational program upon hospital antibiotic use. Am. J. Med. Sci. (1977) 273(1):79-85.
99. SCHROEDER SA, MYERS LP, MCPHEE SJ et al.: The failure of physician education as a cost containment strategy. Report of a prospective controlled trial at a university hospital. JAMA (1984) 252(2):225-230.
100. AVORN J, HARVEY K, SOUMERAI SB et al.: Information and education as determinants of antibiotic use: reports of Task Force 5. Rev. Infect. Dis. (1987) 9(Suppl. 3):S286-S296.
101. SOUMERAI SB: Quality assurance for drug prescribing. Qual. Assur. Healthcare (1990) 2(1):37-58.
102. WILLIAMS RR, GROSS PA, LEVINE JF: Cost containment of the second-generation cephalosporins by prospective monitoring at a community teaching hospital. Arch. Int. Med. (1985) 145(11):1978-1981.
103. BANERJEE A, SALANIPONI F, HARRIES A: Administration of anti-tuberculosis drugs through patient empowerment. Trop. Doctor (1997) 27(4):240.
104. MORRIS LA, HALPERN JA: Effects of written drug information on patient knowledge and compliance: a literature review. Am. J. Public Health (1979) 69(1):47-52.
105. KESSLER RE: Perspectives on chemotherapeutic approaches to antibiotic-resistant bacteria. Clin. Infect. Dis. (1997) 24(Suppl. 1):S146-S147.
106. BAX RP: Antibiotic resistance: a view from the pharmaceutical industry. Clin. Infect. Dis. (1997) 24(Suppl 1):S151-S153.
107. MURRAY BE: Can antibiotic resistance be controlled? New Engl. J. Med. (1994) 330(17):1229-1230.
108. BILLSTEIN SA: How the pharmaceutical industry brings an antibiotic drug to market in the United States. Antimicrob. Agents Chemother. (1994) 38(12):2679-2682.
109. HALEY RW, CUSHION NB, TENOVER FC: Eradication of endemic methicillin-resistant Staphylococcus aureus infections from a neonatal intensive care unit. J. Infect. Dis. (1995) 171(3):614-624.
110. STARLING CE, COUTO BR, PINHEIRO SM: Applying the Centers for Disease Control and Prevention and National Nosocomial Surveillance system methods in Brazilian hospitals. Am. J. Infect. Contr. (1997) 25(4):303-311.
111. JOCHIMSEN EM, FISH L, MANNING K et al. Control of vancomycin-resistant Enterococci at a community hospital. Infect. Contr. Hosp. Epidemiol. (In Preparation).
112. MONTECALVO MA, UMAN J, PETRULLO C et al.: The costbenefit of Enhanced Infection Control Strategies (EICS) to prevent transmission of vancomycinresistant enterococci (VRE). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada. (1997) J-84.
113. CENTERS FOR DISEASE CONTROL: Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Facilities, 1994. MMWR Morb. Mortal. Wkly. Rep. (1994) 44(RR-13):1-132.
114. MALONEY SA, PEARSON ML, GORDON MT et al.: Efficacy of control measures in preventing nosocomial transmission of multidrug-resistant tuberculosis to patients and health care workers. Ann. Int. Med. (1998) 122(2):90-95.
115. WENGER PN, OTTEN J, BREEDEN A et al.: Control of nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis among healthcare workers and HIV-infected patients. Lancet (1995) 345(8944):235-240.
116. JARVIS WR: Handwashing-the Semmelweis lesson forgotten? Lancet (1994) 344(8933):1311-1312.
117. ALBERT RK, CONDIE F: Hand-washing practices in medical intensive-care units. New Engl. J. Med. (1981) 304(24):1465-1466.
118. GRAHAM M: Frequency and duration of handwashing in an intensive care unit. Am. J. Infect. Contr. (1990) 18(2):77-81.
119. ZIMAKOFF J, STORMARK M, LARSEN SO: Use of gloves and handwashing behaviour among health care workers in intensive care units. A multicentre investigation in four hospitals in Denmark and Norway. J. Hosp. Infect. (1993) 24(1):63-67.
120. DOEBBLING BN, STANLEY GL, SHEETZ CT: Comparative efficacy of alternative hand-washing agents in reducing nosocomial infections in intensive care units. New Engl. J. Med. (1992) 327(2):88-93.
121. LARSON EL, BRYAN JL, ADLER LM, BLANE C: A multifaceted approach to changing handwashing behaviour. Am. J. Infect. Contr. (1997) 25(1):3-10.
122. SPROAT LJ, INGLIS TJ: A multicentre survey of hand hygiene practice in intensive care units. J. Hosp. Infect. (1994) 26(2):137-148.
123. DONOWITZ LG: Handwashing technique in a pediatric intensive care unit. Am. J. Dis. Children (1987) 141(6):683-685.
124. DUBBERT PM, DOLCE J, RICHTER W, MILLER M, CHAPMAN SW: Increasing ICU staff handwashing: effects of education and group feedback. Infect. Contr. Hosp. Epidemiol. (1990) 11(4):191-193.
125. LARSON E, MCGEER A, QURAISHI AZ: Effect of an automated sink on handwashing practices and attitudes in high-risk units. Infect. Contr. Hosp. Epidemiol. (1991) 12(7):422-428.
126. SIMMONS B, BRYANT J, NEIMAN K, SPENCER L, ARHEART K: The role of handwashing in prevention of endemic intensive care unit infections. Infect. Contr. Hosp. Epidemiol. (1990) 11(11):589-594.
127. BISHOFF WE, REYNOLDS TM, SESSLER CN, EDMOND MB, WENZEL RP: Handwashing compliance by health care workers: the impact of an education and awareness program. 8th Annual Meeting of the Society for Healthcare Epidemiology. Orlando, Florida, USA (1998). 22.
128. KRETZER EK, LARSON EL: Behavioral interventions to improve infection control practices. Am. J. Infect. Contr. (1998) 26(3):245-253.
129. GARNER JS, FAVERO MS: CDC guideline for handwashing and hospital environmental control, 1985. Infect. Contr. Hosp. Epidemiol. (1986) 7(4):231-243.
130. GARNER JS, THE HOSPITAL INFECTION CONTROL PRACTICES COMMITTEE: Guideline for isolation precautions in hospitals. Infect. Contr. Hosp. Epidemiol. (1996) 17(1):53-80.
131. JERNIGAN JA, CLEMENCE MA, STOTT GA: Control of methicillin-resistant Staphylococcus aureus at a university hospital: one decade later. Infect. Contr. Hosp. Epidemiol. (1995) 16(12):686-696.
132. MOTECALVO MA, HORWITZ H, GEDRIS C et al.: Outbreak of vancomycin, ampicillin and aminoglycosideresistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob. Agents Chemother. (1994) 38(6):1363-1367.
133. WEINSTEIN RA: Epidemiology and control of nosocomial infections in adult intensive care units. Am. J. Med. (1991) 91(3B):179S-184S.
134. WEINER J, ITOKAZU G, NATHAN C, KABINS SA, WEINSTEIN RA: A randomized, double-blind placebocontrolled trial of selective digestive decontamination in a medical-surgical intensive care unit. Clin. Infect. Dis. (1995) 20(4):861-867.
135. VERHOEF J, VERHAGE EA, VISSER MR: A decade of experience with selective decontamination of the digestive tract as prophylaxis for infections in patients in the intensive care unit: what have we learned? Clin. Infect. Dis. (1993) 17(6):1047-1054.
136. REAGAN DR, DOEBBLING BN, PFALLER MA et al.: Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupiricin calcium ointment. Ann. Int. Med. (1991) 114(2):101-106.
137. www.who.int/whr/1996/whr-e.htm Executive summary: Fighting Disease, fostering development. In: The World Health Report 1996. World Health Organisation, Geneva (1996).
138. INSTITUTE OF MEDICINE: Emerging infections: microbial threats to health in the United States. LEDERBERG J, SHOPE RE, OAKS SC (Eds.) National Academy Press, Washington, D.C. (1992).
139. CENTERS FOR DISEASE CONTROL: Addressing emerging infectious diseases threats: a prevention strategy for the United States executive summary. MMWR Morb. Mortal. Wkly. Rep. (1994) 43(RR-5):1-18.
140. SAHM DF, TENOVER FC: Surveillance for the emergence and dissemination of antimicrobial resistance in bacteria. Infect. Dis. Clin. N. Am. (1997) 11(4):767-783.
141. TOLLEFSON L: National antimicrobial resistance monitoring program. Cause (1998) 2(1):2.
142. PUTMAN L: Keeping global tabs on antimicrobial resistance. Lancet (1998) 351(9111):689.
143. GROSS PA: The potential for clinical guidelines to impact appropriate antimicrobial agent use. Infect. Dis. Clin. N. Am. (1997) 11(4):803-812.
144. TENOVER FC, ARBEIT RD, GOERING RV: How to select and interpret molecular strain typing methods for epidemiological studies of bacterial infections: a review for healthcare epidemiologists. Infect. Contr. Hosp. Epidemiol. (1997) 18(6):426-439.
145. BECK-SAGUE C, JARVIS WR, MARTONE WJ: Outbreak investigations. Infect. Contr. Hosp. Epidemiol. (1997) 18(2):138-45.
146. COUPER MR: Strategies for the rational use of antimicrobials. Clin. Infect. Dis. (1997) 24(Suppl. 1):S154-S156.
147. www.who.ch/whr/1998/reports.html Executive summary: Life in the 21st century-A vision for all. In: The World Health Report 1998. World Health Organisation, Geneva (1998).
148. Centers for Disease Control: Status report on childhood immunization initiative: reported cases of selected vaccine-preventable diseases-United States, 1996. MMWR Morb. Mortal. Wkly. Rep. (1997) 46(29):665-671.
149. STYBLO K, MEIJER J: Impact of BCG vaccination programmes in children and young adults on the tuberculosis program. Tubercle (1976) 57(1):17-43.
150. Centers for Disease Control: Development of new vaccines for tuberculosis. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Morb. Mortal. Wkly. Rep. (1998) 47(RR-13):1-6.
151. Centers for Disease Control: Preventing emerging infectious diseases threats: a strategy for the 21st century. Overview of the updated CDC plan. MMWR Morb. Mortal. Wkly. Rep. (1998) 47(RR-15):1-14.
152. WEINSTEIN RA: Nosocomial infection update. Emerg. Infect. Dis. (1998) 4(3):416-420.
153. LEVY SB: Confronting multidrug resistance: a role for each of us. JAMA (1993) 269(14):1840-1842.